Pfizer Total Biopharma Royalty Revenues by Year

Name: Pfizer Total Biopharma Royalty Revenues by Year (PFE)
Creator: Pfizer

Total Biopharma Royalty Revenues (cross-portfolio summary) — Worldwide revenues ($M) ($M)

Quarterly Annual

Pfizer Total Biopharma Royalty Revenues: $1,650M in FY2025, up 16.0% from a year earlier.

Latest, FY2025

1,650

Period ended Dec 31, 2025

Change on a year earlier

+16.0%

1,423 in FY2024

History

4 years

Since FY2022

Sources

Documents cited below

Where the FY2025 figure comes from

“|| Total Royalty revenues included above | $ | 1,650 | $ | 1,423 | 16% | 16% | $ | 1,639 | $ | 1,418 | 16% | $ | 11 | $ | 6 | 94% | 91%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Total Biopharma Royalty Revenues (cross-portfolio summary) — Worldwide revenues ($M) ($M)	Year on year	Source
FY2025	Dec 31, 2025	1,650	+16.0%	Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024	Dec 31, 2024	1,423	+34.5%	Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2023	Dec 31, 2023	1,058	+25.2%	Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2022	Dec 31, 2022	845	–	Form 10-K (filed 2025-02-27) ↗

Breakdown

What makes up total Biopharma Royalty Revenues

Cite this data

StockData. (2026). Pfizer Total Biopharma Royalty Revenues ($M), annual FY2022–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/royalty-rev-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.